Cost-Effectiveness Analysis of a Physician-Implemented Medication Screening Tool in Older Hospitalised Patients in Ireland
A recent randomised controlled trial conducted in an Irish University teaching hospital that evaluated a physician-implemented medication screening tool, demonstrated positive outcomes in terms of a reduction in incident adverse drug reactions.
The present study objective was to evaluate the cost effectiveness of physicians applying this screening tool to older hospitalised patients compared with usual hospital care in the context of the earlier randomised controlled trial.
We used a cost-effectiveness analysis alongside a conventional outcome analysis in a cluster randomised controlled trial. Patients in the intervention arm (n = 360) received a multifactorial intervention consisting of medicines reconciliation, communication with patients’ senior medical team, and generation of a pharmaceutical care plan in addition to usual medical and pharmaceutical care. Control arm patients (n = 372) received usual medical and pharmaceutical care only. Incremental cost effectiveness was examined in terms of costs to the healthcare system and an outcome measure of adverse drug reactions during inpatient hospital stay. Uncertainty in the analysis was explored using a cost-effectiveness acceptability curve.
On average, the intervention arm was more costly but was also more effective. Compared with usual care (control), the intervention was associated with a non-statistically significant increase of €877 (95% confidence interval − €1807, €3561) in the mean healthcare cost, and a statistically significant decrease of − 0.164 (95% confidence interval − 0.257, − 0.070) in the mean number of adverse drug reaction events per patient. The associated incremental cost-effectiveness ratio per adverse drug reaction averted was €5358. The probability of the intervention being cost effective at threshold values of €0, €5000 and €10,000 was 0.236, 0.455 and 0.680, respectively.
Based on the evidence presented, this physician-led intervention is not likely to be cost effective compared with usual hospital care. To inform future healthcare policy decisions in this field, more economic analyses of structured medication reviews by other healthcare professionals and by computerised clinical decision support software need to be conducted.
The authors thank the patients and practitioners who participated in the trial.
GLO, SB, DO, PG, JG, VW and MM wrote the manuscript. GLO, PG and JG analysed the data. SB and DO designed the original research trial. MNO and DO recruited trial participants and gathered the original trial data.
Compliance with Ethical Standards
This research project was funded by the Health Research Board of Ireland (Grant HRA_HSR/2010/14) and the Irish Research Council (GOIPG/2016/635). The funders had no part in the design of the analysis, the collection, analysis and interpretation of the data, the writing of the report or the decision to submit the article for publication.
Conflict of interest
Stephen Byrne and Denis O’Mahony have part ownership in a patent “A Prescription Decision Support System” (based on STOPP/START prescribing rules); the patent was registered with the European Patent Office (Munich); Patent no. 11757950.8–1952. Stephen Byrne and Denis O’Mahony are also involved with two European Commission-funded grants that involve clinical trials in which there is computerised deployment of the STOPP/START criteria as part of an intervention designed to optimise pharmacotherapy in older adults. The first European Commission grant is called “Development and clinical trials of a new Software Engine for the Assessment and Optimization of drug and non-drug Therapy in Older peRsons [SENATOR]”, grant agreement 305930, awarded under the Seventh Framework Programme (FP7). The trial is registered with the US National Institutes of Health (NCT02097654). Denis O’Mahony is coordinator of the SENATOR project. The second European Commission-funded project is called “OPERAM: OPtimising thERapy to prevent Avoidable hospital admissions in the Multimorbid elderly”. OPERAM is funded under the Horizon 2020 programme (PHC 17-2014). The OPERAM trial is based on another software intervention called “Screening Tool to Reduce Inappropriate Prescribing”, which uses STOPP/START rules to assess the pharmacotherapy of older people. The trial is registered with the US National Institutes of Health (NCT02986425). Gary L. O’Brien, Paddy Gillespie, Mark Mulcahy, Valerie Walshe, Marie N. O’Connor, David O’Sullivan and James Gallagher have no conflicts of interest that are directly relevant to the content of this article.
The research ethics committee (institutional review board) of the local teaching hospitals network approved the trial protocol and the trial was registered with the US National Institutes of Health (NCT01467050).
Written consent was sought and obtained from all participating patients prior to enrolment in the study.
Journal of Economic Literature (JEL) Classification
This article is classified as I19 according to the JEL system.
- 1.Organisation for Economic Co-operation and Development. Life expectancy at birth (indicator). 2018. https://data.oecd.org/healthstat/life-expectancy-at-birth.htm. Accessed 26 Jan 2018.
- 13.Christensen M, Lundh A. Medication review in hospitalised patients to reduce morbidity and mortality. Cochrane Database Syst Rev. 2013;(2):CD008986.Google Scholar
- 19.O’Connor MN, O’Sullivan D, Gallagher PF, Eustace J, Byrne S, O’Mahony D. Prevention of hospital-acquired adverse drug reactions in older people using Screening Tool of Older Persons’ Prescriptions and Screening Tool to Alert to Right Treatment criteria: a cluster randomized controlled trial. J Am Geriatr Soc. 2016;64(8):1558–66.CrossRefPubMedGoogle Scholar
- 20.O’Sullivan D, O’Mahony D, O’Connor MN, Gallagher P, Gallagher J, Cullinan S, et al. Prevention of adverse drug reactions in hospitalised older patients using a software-supported structured pharmacist intervention: a cluster randomised controlled trial. Drugs Aging. 2016;33(1):63–73.CrossRefPubMedGoogle Scholar
- 22.Hill-Taylor B, Sketris I, Hayden J, Byrne S, O’Sullivan D, Christie R. Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact. J Clin Pharm Ther. 2013;38(5):360–72.CrossRefPubMedGoogle Scholar
- 24.Prevention of Adverse Drug Events (ADEs) in hospitalised older patients. https://ClinicalTrials.gov/show/NCT01467050. Accessed 21 Jun 2018.
- 26.Economic and Social Research Institute (ESRI) Activity in acute public hospitals in Ireland. Annual report 2012. Ireland. 2013. http://www.hpo.ie/latest_hipe_nprs_reports/HIPE_2012/HIPE_Report_2012.pdf. Accessed 05 Jan 2018.
- 28.Health Information and Quality Authority (HIQA). Guidelines for the economic evaluation of health technologies in Ireland. Ireland. 2017. https://www.hiqa.ie/sites/default/files/2017-10/Draft_HIQA_Economic_Guidelines_2017_consultation.pdf. Accessed 6 Jan 2018.
- 29.Health Service Executive (HSE). Consolidated salary scales in accordance with Financial Emergency Measures in the Public Interest Act 2013. Ireland. 2013. http://www.hse.ie/eng/staff/benefitsservices/pay/July%202013.pdf. Accessed 4 Jan 2018.
- 31.Healthcare Pricing Office (HPO). Hospital in-patient enquiry scheme (HIPE) report 2012. Dublin: Department of Health (DoH); 2012.Google Scholar
- 32.Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015.Google Scholar
- 35.Gillespie P, O’Shea E, Casey D, Murphy K, Devane D, Cooney A, et al. The cost-effectiveness of a structured education pulmonary rehabilitation programme for chronic obstructive pulmonary disease in primary care: the PRINCE cluster randomised trial. BMJ Open. 2013;3(11):e003479.CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Hoch JS, Rockx MA, Krahn AD. Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of “community acquired” syncope. BMC Health Serv Res. 2006;6(1):68.CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Campbell F, Karnon J, Czoski-Murray C, Jones R. A systematic review of the effectiveness and cost-effectiveness of interventions aimed at preventing medication error (medicines reconciliation) at hospital admission. Report for the National Institute for Health and Clinical Excellence as part of the Patient Safety Pilot. Sheffield: The University of Sheffield, School of Health and Related Research; 2007.Google Scholar
- 45.Clinical Trial of a New Software ENgine for the Assessment & Optimization of Drug and Non-drug Therapy in Older peRsons. https://ClinicalTrials.gov/show/NCT02097654. Accessed 21 Jun 2018.
- 46.OPtimising thERapy to Prevent Avoidable Hospital Admissions in the Multimorbid Older People. https://ClinicalTrials.gov/show/NCT02986425. Accessed 21 Jun 2018.
- 47.Dalton K, O’Brien G, O’Mahony D, Byrne S. Computerised interventions designed to reduce potentially inappropriate prescribing in hospitalised older adults: a systematic review and meta-analysis. Age Ageing. 2018. https://doi.org/10.1093/ageing/afy086. Epub ahead of print.
- 57.Patterson SM, Hughes CM, Cardwell C, Lapane KL, Murray AM, Crealey GE. A cluster randomized controlled trial of an adapted US model of pharmaceutical care for nursing home residents in Northern Ireland (Fleetwood Northern Ireland study): a cost-effectiveness analysis. J Am Geriatr Soc. 2011;59(4):586–93.CrossRefPubMedGoogle Scholar